Wordt geladen...
Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
BACKGROUND: Anti-PD-(L)1 agents are standard of care treatments in various cancers but predictive factors for therapy selection are limited. We hypothesised that markers of systemic inflammation would predict adverse outcomes in multiple cancers treated with anti-PD-(L)1 agents. MATERIAL AND METHODS...
Bewaard in:
| Gepubliceerd in: | ESMO Open |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BMJ Publishing Group
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6735669/ https://ncbi.nlm.nih.gov/pubmed/31555483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000531 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|